|
EA029793B1
(ru)
*
|
2010-08-23 |
2018-05-31 |
Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем |
Антитела к ох40 и способы их применения
|
|
TR201807040T4
(tr)
*
|
2011-07-11 |
2018-06-21 |
Glenmark Pharmaceuticals Sa |
Ox40 a bağlanan antikorlar ve bunların kullanımları.
|
|
AU2012299421B2
(en)
*
|
2011-08-23 |
2016-02-04 |
Board Of Regents, The University Of Texas System |
Anti-OX40 antibodies and methods of using the same
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
PT2925350T
(pt)
|
2012-12-03 |
2019-03-25 |
Bristol Myers Squibb Co |
Melhoria da atividade anticancerosa de proteínas de fusão de fc imunomoduladoras
|
|
PL2964638T3
(pl)
|
2013-03-06 |
2018-01-31 |
Astrazeneca Ab |
Inhibitory chinazolinowe aktywujących zmutowanych postaci receptora epidermalnego czynnika wzrostu
|
|
KR20160006168A
(ko)
*
|
2013-03-18 |
2016-01-18 |
바이오서오엑스 프로덕스 비.브이. |
인간화 항-cd134(ox40) 항체 및 이의 용도
|
|
AU2014304931B2
(en)
|
2013-08-08 |
2018-05-10 |
Assistance Publique - Hopitaux De Paris |
IL-15 and IL-15Raplha sushi domain based modulokines
|
|
AU2014352749A1
(en)
*
|
2013-11-22 |
2016-06-09 |
Dnatrix, Inc. |
Adenovirus expressing immune cell stimulatory receptor agonist(s)
|
|
US20150190506A1
(en)
|
2013-12-17 |
2015-07-09 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
EP3322443A1
(en)
*
|
2015-07-13 |
2018-05-23 |
Yeda Research and Development Co. Ltd |
Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
|
|
RU2690670C2
(ru)
*
|
2014-03-12 |
2019-06-05 |
Ида Рисерч Энд Дивелопмент Ко., Лтд |
Снижение уровней или активности системных регуляторных т-клеток для лечения заболевания или повреждения цнс
|
|
BR112016022345A2
(pt)
|
2014-03-31 |
2017-10-10 |
Genentech Inc |
terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40
|
|
KR20170002410A
(ko)
|
2014-04-03 |
2017-01-06 |
오거스타 유니버시티 리서치 인스티튜트, 인크. |
종양 유도 면역 반응의 효능을 향상시키는 방법
|
|
MX389684B
(es)
|
2014-08-19 |
2025-03-20 |
Merck Sharp & Dohme Llc |
Anticuerpos anti tigit.
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
EP3206711B1
(en)
|
2014-10-14 |
2023-05-31 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
|
CA2966042A1
(en)
|
2014-10-31 |
2016-05-06 |
Oncomed Pharmaceuticals, Inc. |
Combination therapy for treatment of disease
|
|
US20160160290A1
(en)
|
2014-11-03 |
2016-06-09 |
Genentech, Inc. |
Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
|
SG11201703448QA
(en)
*
|
2014-11-03 |
2017-05-30 |
Genentech Inc |
Assays for detecting t cell immune subsets and methods of use thereof
|
|
KR20170072343A
(ko)
|
2014-11-06 |
2017-06-26 |
제넨테크, 인크. |
Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
|
|
MX2017006320A
(es)
|
2014-11-17 |
2017-08-10 |
Genentech Inc |
Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
|
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
|
MA41460A
(fr)
|
2015-02-03 |
2017-12-12 |
Oncomed Pharm Inc |
Agents de liaison à la tnfrsf et leurs utilisations
|
|
CN108064169B
(zh)
|
2015-03-03 |
2022-02-11 |
科马布有限公司 |
抗体、用途和方法
|
|
EP3268037B1
(en)
|
2015-03-09 |
2022-08-31 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
|
KR20180002653A
(ko)
|
2015-04-07 |
2018-01-08 |
제넨테크, 인크. |
효능작용 활성을 갖는 항원 결합 복합체 및 사용 방법
|
|
BR112017023849A2
(pt)
|
2015-05-07 |
2018-07-17 |
Agenus Inc. |
anticorpos anti-ox40 e métodos de uso dos mesmos
|
|
CN108137687B
(zh)
|
2015-05-29 |
2021-10-29 |
百时美施贵宝公司 |
抗ox40抗体及其用途
|
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
WO2017019894A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
|
WO2017021913A1
(en)
|
2015-08-04 |
2017-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
CA2994635A1
(en)
*
|
2015-08-04 |
2017-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
US20180222989A1
(en)
*
|
2015-08-04 |
2018-08-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
WO2017021912A1
(en)
|
2015-08-06 |
2017-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combined tlrs modulators with anti ox40 antibodies
|
|
TW201716084A
(zh)
|
2015-08-06 |
2017-05-16 |
葛蘭素史克智慧財產發展有限公司 |
組合物及其用途與治療
|
|
US20180230431A1
(en)
|
2015-08-07 |
2018-08-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Therapy
|
|
CN115925931A
(zh)
|
2015-08-14 |
2023-04-07 |
默沙东公司 |
抗tigit抗体
|
|
CN107949573B
(zh)
|
2015-09-01 |
2022-05-03 |
艾吉纳斯公司 |
抗-pd-1抗体及其使用方法
|
|
WO2017046746A1
(en)
|
2015-09-15 |
2017-03-23 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
|
|
AU2016329120B2
(en)
|
2015-10-02 |
2023-04-13 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specific for a costimulatory TNF receptor
|
|
US10624974B2
(en)
|
2015-10-15 |
2020-04-21 |
Dingfu Biotarget Co., Ltd. |
Anti-OX40 antibody and application thereof
|
|
EA201891093A1
(ru)
|
2015-11-03 |
2018-10-31 |
Янссен Байотек, Инк. |
Антитела, специфически связывающие pd-1, и их применение
|
|
GB201520903D0
(en)
|
2015-11-26 |
2016-01-13 |
Qbd Qs Ip Ltd |
Purification method
|
|
JP2019505476A
(ja)
|
2015-12-01 |
2019-02-28 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
組合せ処置およびその方法
|
|
MX2018006477A
(es)
*
|
2015-12-02 |
2018-09-03 |
Agenus Inc |
Anticuerpos y metodos de uso de estos.
|
|
MA43389A
(fr)
*
|
2015-12-02 |
2021-05-12 |
Agenus Inc |
Anticorps anti-ox40 et leurs procédés d'utilisation
|
|
WO2017093933A1
(en)
|
2015-12-03 |
2017-06-08 |
Glaxosmithkline Intellectual Property Development Limited |
Cyclic purine dinucleotides as modulators of sting
|
|
WO2017096182A1
(en)
*
|
2015-12-03 |
2017-06-08 |
Agenus Inc. |
Anti-ox40 antibodies and methods of use thereof
|
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
|
EP3389712B1
(en)
|
2015-12-17 |
2024-04-10 |
Novartis AG |
Antibody molecules to pd-1 and uses thereof
|
|
SG10201601719RA
(en)
|
2016-03-04 |
2017-10-30 |
Agency Science Tech & Res |
Anti-LAG-3 Antibodies
|
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
|
ES2781474T3
(es)
|
2016-04-07 |
2020-09-02 |
Glaxosmithkline Ip Dev Ltd |
Amidas heterocíclicas útiles como moduladores de proteínas
|
|
PE20181884A1
(es)
|
2016-04-07 |
2018-12-07 |
Glaxosmithkline Ip Dev Ltd |
Amidas heterociclicas utiles como moduladores de proteinas
|
|
KR20190003699A
(ko)
|
2016-05-05 |
2019-01-09 |
글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 |
제스트 인핸서 상동체 2 억제제
|
|
SG10201603721TA
(en)
|
2016-05-10 |
2017-12-28 |
Agency Science Tech & Res |
Anti-CTLA-4 Antibodies
|
|
KR102531889B1
(ko)
|
2016-06-20 |
2023-05-17 |
키맵 리미티드 |
항-pd-l1 및 il-2 사이토카인
|
|
BR112019001136A2
(pt)
|
2016-07-20 |
2019-04-30 |
Glaxosmithkline Ip Dev Ltd |
compostos químicos
|
|
WO2018025221A1
(en)
|
2016-08-04 |
2018-02-08 |
Glaxosmithkline Intellectual Property Development Limited |
Anti-icos and anti-pd-1 antibody combination therapy
|
|
US11046776B2
(en)
|
2016-08-05 |
2021-06-29 |
Genentech, Inc. |
Multivalent and multiepitopic antibodies having agonistic activity and methods of use
|
|
WO2018031400A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
|
|
WO2018031258A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
|
|
WO2018041119A1
(en)
|
2016-08-31 |
2018-03-08 |
Beijing Biocytogen Co., Ltd |
Genetically modified non-human animal with human or chimeric ox40
|
|
CN107815465B
(zh)
|
2016-08-31 |
2021-03-16 |
百奥赛图(北京)医药科技股份有限公司 |
人源化基因改造动物模型的制备方法及应用
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
EP3538152A4
(en)
|
2016-11-09 |
2020-09-30 |
Agenus Inc. |
ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE
|
|
JP2020511407A
(ja)
|
2016-12-01 |
2020-04-16 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
併用療法
|
|
CA3045241A1
(en)
|
2016-12-01 |
2018-06-07 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
|
TWI734879B
(zh)
*
|
2016-12-15 |
2021-08-01 |
美商艾伯維生物醫療股份有限公司 |
抗ox40抗體及其用途
|
|
MX2019007144A
(es)
|
2016-12-19 |
2019-10-07 |
Glenmark Pharmaceuticals Sa |
Nuevos agonistas de tnfr y sus usos.
|
|
IL267780B2
(en)
|
2017-01-06 |
2024-11-01 |
Iovance Biotherapeutics Inc |
Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
|
|
EP3582855A1
(en)
|
2017-02-15 |
2019-12-25 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatment for cancer
|
|
WO2018154520A1
(en)
|
2017-02-27 |
2018-08-30 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides as kinase inhibitors
|
|
CN108623686A
(zh)
|
2017-03-25 |
2018-10-09 |
信达生物制药(苏州)有限公司 |
抗ox40抗体及其用途
|
|
US11819517B2
(en)
|
2017-06-05 |
2023-11-21 |
Iovance Biotherapeutics, Inc. |
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
|
|
EP3635011A1
(en)
|
2017-06-09 |
2020-04-15 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination therapy with icos agonist and ox40 agonist to treat cancer
|
|
BR112019025257A2
(pt)
|
2017-06-09 |
2020-09-29 |
Glaxosmithkline Intellectual Property Development Limited |
método para tratar câncer, e, anticorpo anti-icos ou porção de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou porção de ligação ao antígeno do mesmo
|
|
WO2019021208A1
(en)
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
|
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
CHEMICAL COMPOUNDS
|
|
EP3681541A4
(en)
|
2017-09-13 |
2021-05-26 |
Radimmune Therapeutics, Inc. |
MELANINE ANTIBODIES AND USES THEREOF
|
|
JP2020536106A
(ja)
|
2017-10-05 |
2020-12-10 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
Ｈｉｖの処置に有用なインターフェロン遺伝子の刺激物質（ｓｔｉｎｇ）の調節物質
|
|
US11377440B2
(en)
|
2017-10-05 |
2022-07-05 |
Glaxosmithkline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (STING)
|
|
EP3704159A1
(en)
|
2017-11-01 |
2020-09-09 |
Bristol-Myers Squibb Company |
Immunostimulatory agonistic antibodies for use in treating cancer
|
|
CA3082484A1
(en)
|
2017-11-17 |
2019-05-23 |
Iovance Biotherapeutics, Inc. |
Til expansion from fine needle aspirates and small biopsies
|
|
WO2019106605A1
(en)
|
2017-12-01 |
2019-06-06 |
Board Of Regents, The University Of Texas System |
Combination treatment for cancer
|
|
US11142579B2
(en)
|
2017-12-06 |
2021-10-12 |
Sorrento Therapeutics, Inc. |
Variant antibodies that bind OX40
|
|
CN118047873A
(zh)
*
|
2017-12-29 |
2024-05-17 |
圆祥生技股份有限公司 |
调节免疫检查点作为癌症治疗的单特异性蛋白质
|
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
US11713446B2
(en)
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
|
BR112020013848A2
(pt)
|
2018-01-08 |
2020-12-01 |
Iovance Biotherapeutics, Inc. |
métodos para expandir linfócitos infiltrantes de tumor e para tratar um indivíduo com câncer, população de linfócitos infiltrantes de tumor, e, método para avaliar fatores de transcrição
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
CN111393529B
(zh)
*
|
2018-01-29 |
2022-02-22 |
康源博创生物科技(北京)有限公司 |
与ox40l非竞争结合的抗ox40抗体
|
|
MA51875A
(fr)
|
2018-02-13 |
2020-12-23 |
Iovance Biotherapeutics Inc |
Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
|
|
TW202003555A
(zh)
*
|
2018-03-07 |
2020-01-16 |
英商葛蘭素史克智慧財產發展有限公司 |
用於純化重組多肽之方法
|
|
JP7351845B2
(ja)
|
2018-03-23 |
2023-09-27 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
|
|
CN110305210B
(zh)
|
2018-03-27 |
2023-02-28 |
信达生物制药(苏州)有限公司 |
新型抗体分子、其制备方法及其用途
|
|
WO2019184909A1
(zh)
|
2018-03-27 |
2019-10-03 |
信达生物制药(苏州)有限公司 |
新型抗体分子、其制备方法及其用途
|
|
EP3784254A1
(en)
|
2018-04-27 |
2021-03-03 |
Iovance Biotherapeutics, Inc. |
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
CA3103040A1
(en)
*
|
2018-05-11 |
2019-11-14 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Fully human antibodies against ox40, method for preparing same, and use thereof
|
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
|
JP7489922B2
(ja)
*
|
2018-05-23 |
2024-05-24 |
ベイジーン リミテッド |
抗ｏｘ４０抗体及び使用方法
|
|
WO2019241730A2
(en)
|
2018-06-15 |
2019-12-19 |
Flagship Pioneering Innovations V, Inc. |
Increasing immune activity through modulation of postcellular signaling factors
|
|
WO2020014583A1
(en)
|
2018-07-13 |
2020-01-16 |
Bristol-Myers Squibb Company |
Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor
|
|
US12195533B2
(en)
|
2018-07-24 |
2025-01-14 |
Inhibrx Biosciences, Inc. |
Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the same
|
|
WO2020030570A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
|
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
|
|
US20220322655A1
(en)
|
2018-09-20 |
2022-10-13 |
Iovance Biotherapeutics, Inc. |
Expansion of TILs from Cryopreserved Tumor Samples
|
|
KR20210069058A
(ko)
*
|
2018-09-26 |
2021-06-10 |
지앙수 헨그루이 메디슨 컴퍼니 리미티드 |
항-ox40 항체, 이의 항원-결합 단편 및 약학적 용도
|
|
CA3115089A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
|
CN120623346A
(zh)
|
2018-10-11 |
2025-09-12 |
因荷布瑞克斯生物科学公司 |
Pd-1单结构域抗体及其治疗组合物
|
|
AU2019377422A1
(en)
|
2018-11-05 |
2021-05-27 |
Iovance Biotherapeutics, Inc. |
Treatment of NSCLC patients refractory for anti-PD-1 antibody
|
|
EP3877513B1
(en)
|
2018-11-05 |
2025-05-07 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
US12343380B2
(en)
|
2018-11-05 |
2025-07-01 |
Iovance Biotherapeutics, Inc. |
Expansion of TILs utilizing AKT pathways inhibitors
|
|
KR20210099573A
(ko)
|
2018-11-05 |
2021-08-12 |
이오반스 바이오테라퓨틱스, 인크. |
개선된 종양 반응성 t-세포의 선택
|
|
CN113348180B
(zh)
*
|
2018-11-20 |
2023-05-26 |
上海开拓者生物医药有限公司 |
Ox40抗体及其制备方法和应用
|
|
EP3898949A1
(en)
|
2018-12-19 |
2021-10-27 |
Iovance Biotherapeutics, Inc. |
Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
|
|
US10442866B1
(en)
*
|
2019-01-23 |
2019-10-15 |
Beijing Mabworks Biotech Co. Ltd |
Antibodies binding OX40 and uses thereof
|
|
AU2020214412A1
(en)
|
2019-02-01 |
2021-08-12 |
Glaxosmithkline Intellectual Property Development Limited |
Belantamab mafodotin in combination with pembrolizumab for treating cancer
|
|
JP7760374B2
(ja)
|
2019-03-29 |
2025-10-27 |
ターンストーン バイオロジクス コーポレイション |
Ｔ細胞治療薬を生成するためのエクスビボ方法ならびに関連する組成物および方法
|
|
WO2020227159A2
(en)
|
2019-05-03 |
2020-11-12 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity
|
|
WO2020232029A1
(en)
|
2019-05-13 |
2020-11-19 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
CN114302875A
(zh)
|
2019-05-16 |
2022-04-08 |
斯汀塞拉股份有限公司 |
氧代吖啶基乙酸衍生物及使用方法
|
|
JP2022533194A
(ja)
|
2019-05-16 |
2022-07-21 |
スティングセラ インコーポレイテッド |
ベンゾ［ｂ］［１，８］ナフチリジン酢酸誘導体および使用方法
|
|
US20220233691A1
(en)
|
2019-05-30 |
2022-07-28 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
|
WO2020243568A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
|
|
US20220363760A1
(en)
|
2019-05-30 |
2022-11-17 |
Bristol-Myers Squibb Company |
Multi-tumor gene signature for suitability to immuno-oncology therapy
|
|
CA3143211A1
(en)
|
2019-06-26 |
2020-12-30 |
Glaxosmithkline Intellectual Property Development Limited |
Il1rap binding proteins
|
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
EP4011389A4
(en)
*
|
2019-08-09 |
2024-09-04 |
Riken |
COMBINED USE OF ARTIFICIAL AUXILIARY VECTOR CELLS AND IMMUNE STIMULANT
|
|
WO2021043961A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
|
|
JP7280387B2
(ja)
|
2019-09-27 |
2023-05-23 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
抗原結合タンパク質
|
|
JP2022553389A
(ja)
|
2019-10-25 |
2022-12-22 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍浸潤リンパ球の遺伝子編集及び免疫療法におけるその使用
|
|
KR20220122639A
(ko)
|
2019-11-27 |
2022-09-02 |
미스트 쎄라퓨틱스, 엘엘씨 |
조절제를 이용한 종양 반응성 t 세포 조성물의 제조 방법
|
|
US20230220341A1
(en)
|
2019-12-11 |
2023-07-13 |
lovance Biotherapeutics, Inc. |
Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
|
|
CR20220341A
(es)
*
|
2019-12-17 |
2022-08-19 |
Amgen Inc |
Agonista doble de interleucina-2/receptor de tnf para uso en terapia
|
|
JP2023509359A
(ja)
|
2019-12-17 |
2023-03-08 |
フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド |
鉄依存性細胞分解の誘導物質との併用抗癌療法
|
|
CA3164751A1
(en)
|
2019-12-18 |
2021-06-24 |
Benjamin Joseph MORROW |
Compounds
|
|
CN113135994A
(zh)
*
|
2020-01-19 |
2021-07-20 |
迈威(上海)生物科技股份有限公司 |
一种激活型抗ox40抗体、生产方法及应用
|
|
US20230067202A1
(en)
|
2020-01-28 |
2023-03-02 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Treatments and Uses and Methods Thereof
|
|
EP4110799B1
(en)
|
2020-02-27 |
2024-11-06 |
Turnstone Biologics Corp. |
Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof
|
|
US20230293685A1
(en)
|
2020-05-04 |
2023-09-21 |
Iovance Biotherapeutics, Inc. |
Selection of improved tumor reactive t-cells
|
|
US20230172987A1
(en)
|
2020-05-04 |
2023-06-08 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
US20230355804A1
(en)
|
2020-06-29 |
2023-11-09 |
Flagship Pioneering Innovations V, Inc. |
Viruses engineered to promote thanotransmission and their use in treating cancer
|
|
CN112442121A
(zh)
*
|
2020-08-20 |
2021-03-05 |
山东兴瑞生物科技有限公司 |
Ox40抗体、其编码基因、及抗体的制备方法和在增强人体免疫功能中的应用
|
|
CN116438199A
(zh)
|
2020-08-31 |
2023-07-14 |
百时美施贵宝公司 |
细胞定位特征和免疫疗法
|
|
EP4225330A1
(en)
|
2020-10-06 |
2023-08-16 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
WO2022074206A1
(en)
|
2020-10-08 |
2022-04-14 |
Affimed Gmbh |
Trispecific binders
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
CA3201818A1
(en)
|
2020-12-11 |
2022-06-16 |
Maria Fardis |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
|
|
JP2024500403A
(ja)
|
2020-12-17 |
2024-01-09 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍浸潤リンパ球によるがんの治療
|
|
JP2023554395A
(ja)
|
2020-12-17 |
2023-12-27 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
Ｃｔｌａ－４及びｐｄ－１阻害剤と併用した腫瘍浸潤リンパ球療法による治療
|
|
EP4267105B1
(en)
|
2020-12-28 |
2025-03-26 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
JP2024501029A
(ja)
|
2020-12-28 |
2024-01-10 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
|
|
CA3209479A1
(en)
|
2021-02-03 |
2022-08-11 |
Mozart Therapeutics, Inc. |
Binding agents and methods of using the same
|
|
CN112957475B
(zh)
*
|
2021-02-04 |
2022-07-22 |
李文峰 |
一种预防和或治疗肿瘤的组合物及应用
|
|
IL305427A
(en)
|
2021-03-02 |
2023-10-01 |
Glaxosmithkline Ip Dev Ltd |
Substituted pyridines as DNMT1 inhibitors
|
|
CA3214085A1
(en)
|
2021-03-31 |
2022-10-06 |
Darby Rye Schmidt |
Thanotransmission polypeptides and their use in treating cancer
|
|
JP2024511831A
(ja)
|
2021-03-31 |
2024-03-15 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
抗原結合タンパク質およびそれらの組み合わせ
|
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
切断型ｃｄｃｐ１に対する抗体およびその使用
|
|
US20240207318A1
(en)
|
2021-04-19 |
2024-06-27 |
Yongliang Zhang |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
|
US20240316104A1
(en)
|
2021-06-29 |
2024-09-26 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
|
EP4377446A1
(en)
|
2021-07-28 |
2024-06-05 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
|
US20240376208A1
(en)
|
2021-07-30 |
2024-11-14 |
Affimed Gmbh |
Duplexbodies
|
|
CA3232700A1
(en)
|
2021-09-24 |
2023-03-30 |
Rafael CUBAS |
Expansion processes and agents for tumor infiltrating lymphocytes
|
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
|
WO2023077015A2
(en)
|
2021-10-27 |
2023-05-04 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
|
EP4430167A1
(en)
|
2021-11-10 |
2024-09-18 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
|
WO2023147486A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Tumor infiltrating lymphocytes engineered to express payloads
|
|
EP4475879A1
(en)
|
2022-02-08 |
2024-12-18 |
Hookipa Biotech GmbH |
Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
|
|
JP2025509832A
(ja)
|
2022-03-15 |
2025-04-11 |
コンピュジェン リミテッド |
Ｉｌ－１８ｂｐアンタゴニスト抗体、並びに癌の治療での単剤療法及び併用療法におけるそれらの使用
|
|
US20250206775A1
(en)
|
2022-03-18 |
2025-06-26 |
Bristol-Myers Squibb Company |
Methods of isolating polypeptides
|
|
EP4507704A1
(en)
|
2022-04-15 |
2025-02-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
|
EP4531916A1
(en)
|
2022-06-02 |
2025-04-09 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
EP4565683A1
(en)
|
2022-08-01 |
2025-06-11 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
|
WO2024054992A1
(en)
|
2022-09-09 |
2024-03-14 |
Bristol-Myers Squibb Company |
Methods of separating chelator
|
|
JP2025532464A
(ja)
|
2022-09-15 |
2025-10-01 |
アビディキュア アイピー ビー．ブイ． |
Ｎｋ細胞の腫瘍標的化のための多重特異性抗原結合タンパク質及びその使用
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
WO2024151885A1
(en)
|
2023-01-13 |
2024-07-18 |
Iovance Biotherapeutics, Inc. |
Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
|
|
WO2024196952A1
(en)
|
2023-03-20 |
2024-09-26 |
Bristol-Myers Squibb Company |
Tumor subtype assessment for cancer therapy
|
|
AR132668A1
(es)
|
2023-05-12 |
2025-07-16 |
Genmab As |
Anticuerpos capaces de unirse a ox40, variantes de los mismos y usos de los mismos
|
|
TW202515608A
(zh)
|
2023-06-26 |
2025-04-16 |
以色列商坎布根有限公司 |
Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
|
|
WO2025021131A1
(en)
*
|
2023-07-25 |
2025-01-30 |
Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. |
Methods of treating alopecia areata and atopic dermatitis
|
|
WO2025038763A1
(en)
|
2023-08-15 |
2025-02-20 |
Bristol-Myers Squibb Company |
Ceramic hydroxyapatite chromatography flow through method
|
|
WO2025101484A1
(en)
|
2023-11-06 |
2025-05-15 |
Iovance Biotherapeutics, Inc. |
Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
|
|
WO2025114541A1
(en)
|
2023-11-30 |
2025-06-05 |
Genmab A/S |
Antibodies capable of binding to ox40 in combination therapy
|
|
US20250215087A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg depleting agent
|
|
WO2025191136A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
|
|
WO2025191133A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Il-21 muteins, fusion proteins comprising the same and uses thereof
|